keyword
MENU ▼
Read by QxMD icon Read
search

Bladder cancer, cystectomy

keyword
https://www.readbyqxmd.com/read/28105663/lymphocyte-to-monocyte-ratio-and-neutrophil-to-lymphocyte-ratio-as-biomarkers-for-predicting-lymph-node-metastasis-and-survival-in-patients-treated-with-radical-cystectomy
#1
David D'Andrea, Marco Moschini, Kilian M Gust, Mohammad Abufaraj, Mehmet Özsoy, Romain Mathieu, Francesco Soria, Alberto Briganti, Morgan Rouprêt, Pierre I Karakiewicz, Shahrokh F Shariat
PURPOSE: To evaluate the role of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) as pre-operative markers for predicting extravesical disease and survival outcomes in patients undergoing radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB). MATERIALS AND METHODS: Data from 4335 patients undergoing RC for clinically non-metastatic UCB were analyzed. Multivariable logistic regression models were used to predict lymph node involvement and extravesical disease (defined as ≥pT3 and N0)...
January 20, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28104421/assessing-cancer-progression-and-stable-disease-after-neoadjuvant-chemotherapy-for-organ-confined-muscle-invasive-bladder-cancer
#2
Meera R Chappidi, Max Kates, Aaron Brant, Alexander S Baras, George J Netto, Phillip M Pierorazio, Noah M Hahn, Trinity J Bivalacqua
OBJECTIVE: To propose and validate a new approach to stratify clinically staged organ-confined muscle-invasive bladder cancer patients (cT2N0M0) that are pathologic non-responders to neoadjuvant chemotherapy (NAC) to better characterize NAC non-response. METHODS: We retrospectively identified radical cystectomy patients with cT2N0M0 disease at our institution (2005-2014) and in the National Cancer Database (NCDB, 2004-2012) for external validation. Patients were stratified as stable (pT2N0M0) or progressors (>pT2 and/or pN+)...
January 16, 2017: Urology
https://www.readbyqxmd.com/read/28087131/incidence-and-effect-of-variant-histology-on-oncological-outcomes-in-patients-with-bladder-cancer-treated-with-radical-cystectomy
#3
Marco Moschini, Paolo Dell'Oglio, Roberta Luciano', Giorgio Gandaglia, Francesco Soria, Agostino Mattei, Tobias Klatte, Rocco Damiano, Shahrokh F Shariat, Andrea Salonia, Francesco Montorsi, Alberto Briganti, Renzo Colombo, Andrea Gallina
INTRODUCTION: We sought to describe incidence of histological variants after radical cystectomy (RC) due to bladder cancer (BCa). Moreover, we investigated survival outcomes accounting for this parameter. METHODS: We retrospectively evaluated data from 1,067 patients with BCa treated with RC between 1990 and 2013 at a single tertiary care referral center. All specimen were evaluated by dedicated uropathologists. Univariable and multivariable Cox regression analyses tested the effect of different histopathological variant on recurrence, cancer-specific mortality (CSM), and overall mortality (OM) after accounting for all available confounders...
January 10, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28078533/risk-factors-for-intravesical-recurrence-after-nephroureterectomy-in-patients-with-upper-urinary-tract-urothelial-carcinoma
#4
Ryo Yamashita, Reiko Watanabe, Ichiro Ito, Hideo Shinsaka, Masafumi Nakamura, Masato Matsuzaki, Masashi Niwakawa
PURPOSE: To determine major risk factors for bladder cancer (BC) recurrence after nephroureterectomy (Nux) by focusing on the pathologic appearances of tumors in upper urinary tract urothelial carcinomas (UUTUCs). METHODS: We performed 147 Nux procedures between November 2002 and September 2015. Forty-eight patients were excluded because of a history of BC (28 patients), previous or concurrent radical cystectomy (9 patients), neoadjuvant chemotherapy (5 patients), and other reasons (6 patients)...
January 11, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28069289/liquid-biopsy-analysis-of-fgfr3-and-pik3ca-hotspot-mutations-for-disease-surveillance-in-bladder-cancer
#5
Emil Christensen, Karin Birkenkamp-Demtröder, Iver Nordentoft, Søren Høyer, Kirstin van der Keur, Kim van Kessel, Ellen Zwarthoff, Mads Agerbæk, Torben Falck Ørntoft, Jørgen Bjerggaard Jensen, Lars Dyrskjøt
BACKGROUND: Disease surveillance in patients with bladder cancer is important for early diagnosis of progression and metastasis and for optimised treatment. OBJECTIVE: To develop urine and plasma assays for disease surveillance for patients with FGFR3 and PIK3CA tumour mutations. DESIGN, SETTING, AND PARTICIPANTS: Droplet digital polymerase chain reaction (ddPCR) assays were developed and tumour DNA from two patient cohorts was screened for FGFR3 and PIK3CA hotspot mutations...
January 6, 2017: European Urology
https://www.readbyqxmd.com/read/28049550/gec-estro-acrop-recommendations-for-performing-bladder-sparing-treatment-with-brachytherapy-for-muscle-invasive-bladder-carcinoma
#6
Bradley R Pieters, Elzbieta van der Steen-Banasik, Geert A Smits, Marisol De Brabandere, Alberto Bossi, Erik Van Limbergen
The standard treatment for muscle-invasive bladder cancer (MIBC) is a radical cystectomy with pelvic lymph node dissection with or without neoadjuvant chemotherapy. In selected cases a bladder sparing approach is possible, for example a limited surgical excision combined with external beam radiotherapy and brachytherapy. To perform brachytherapy flexible catheters have to be implanted in the bladder wall. The implantation is done either by the open retropubic approach or the endoscopic surgical approach. The largest experience for brachytherapy is with low-dose rate and pulsed-dose rate, although some short-term experience with high-dose rate is also reported...
December 31, 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28040422/pure-but-not-mixed-histologic-variants-are-associated-with-poor-survival-at-radical-cystectomy-in-bladder-cancer-patients
#7
Marco Moschini, Shahrokh F Shariat, Roberta Lucianò, David D'Andrea, Beat Foerster, Mohammad Abufaraj, Marco Bandini, Paolo Dell'Oglio, Rocco Damiano, Andrea Salonia, Francesco Montorsi, Alberto Briganti, Renzo Colombo, Andrea Gallina
PURPOSE: To evaluate the impact of pure and mixed histologic variant versus pure urothelial carcinoma in nonmetastatic bladder cancer (BCa) patients treated with radical cystectomy (RC). PATIENTS AND METHODS: We evaluated data from 1067 patients treated with RC and pelvic lymph node dissection between 1990 and 2013 at a single institution tertiary-care referral center. All specimens were evaluated by dedicated uropathologists. Univariable and multivariable Cox regression analyses tested the impact of the presence of pure and mixed histologic variants versus pure urothelial on recurrence, cancer-specific mortality, and overall mortality after accounting for all available confounders...
December 14, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28040419/a-novel-treatment-strategy-for-newly-diagnosed-high-grade-t1-bladder-cancer-gemcitabine-and-cisplatin-adjuvant-chemotherapy-a-single-institution-experience
#8
Guo-Liang Yang, Lian-Hua Zhang, Qiang Liu, Zhao-Liang Wang, Xue-Hui Duan, Yi-Ran Huang, Juan-Jie Bo
BACKGROUND: Management of high-grade T1 (formerly T1G3) bladder cancer continues to be controversial. Should patients with T1G3 bladder cancer have an immediate radical cystectomy or should they receive intravesical bacillus Calmette-Guérin-preserving bladder? Gemcitabine and cisplatin (GC) adjuvant chemotherapy may help to strike a balance between intravesical and early cystectomy. For purposes of this study, we continue to refer high-grade T1 lesion as "T1G3." OBJECTIVE: To evaluate the characteristics and the long-term outcome of GC adjuvant chemotherapy in T1G3 bladder cancer after transurethral resection of bladder tumor (TURBT)...
February 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28040351/clinical-outcomes-of-patients-with-histologic-variants-of-urothelial-cancer-treated-with-trimodality-bladder-sparing-therapy
#9
Ross E Krasnow, Michael Drumm, Hannah J Roberts, Andrzej Niemierko, Chin-Lee Wu, Shulin Wu, Jing Zhang, Niall M Heney, Matthew F Wszolek, Michael L Blute, Adam S Feldman, Richard J Lee, Anthony L Zietman, William U Shipley, Jason A Efstathiou
BACKGROUND: Trimodality bladder-sparing therapy (TMT) is an acceptable treatment for selected patients with muscle-invasive urothelial cancer. Outcomes of TMT in histologic variants remains largely unknown. OBJECTIVE: To compare outcomes of pure urothelial carcinoma (PUC) to variant urothelial carcinoma (VUC) after TMT. DESIGN, SETTING, AND PARTICIPANTS: Retrospective study of patients treated with TMT at a single cancer center from 1993 until 2013...
December 28, 2016: European Urology
https://www.readbyqxmd.com/read/28035325/effect-of-neoadjuvant-chemotherapy-on-renal-function-following-radical-cystectomy-is-there-a%C3%A2-meaningful-impact
#10
Thenappan Chandrasekar, Neil Pugashetti, Blythe Durbin-Johnson, Marc A Dall'Era, Christopher P Evans, Ralph W deVere White, Stanley A Yap
Objective: To evaluate the patterns of impact of neoadjuvant chemotherapy (NAC) on renal function across the initial year following treatment for muscle-invasive bladder cancer (MIBC) with radical cystectomy (RC). Methods: We reviewed the charts of 241 patients who underwent RC for urothelial carcinoma of the bladder between 2003-14 at our institution. Renal function was evaluated at multiple time points (pre-chemotherapy, pre-operatively, post-operatively, 6-12 months follow-up), and then classified by CKD staging...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035322/micropapillary-bladder-cancer-insights-from-the-national-cancer-database
#11
Wilson Sui, Justin T Matulay, Maxwell B James, Ifeanyi C Onyeji, Marissa C Theofanides, Arindam RoyChoudhury, G Joel DeCastro, Sven Wenske
Introduction: Micropapillary bladder cancer (MPBC) is a variant histology of urothelial carcinoma (UC) that is associated with poor outcomes however given its rarity, little is known outside of institutional reports. We sought to use a population-level cancer database to assess survival outcomes in patients treated with surgery, radiation therapy and/or chemotherapy. Materials and Methods: The National Cancer Database (NCDB) was queried for all cases of MPBC and UC using International Classification of Disease-O-3 morphologic codes between 2004-2014...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035321/patterns-of-bladder-preservation-therapy%C3%A2-utilization-for-muscle-invasive-bladder-cancer
#12
Tracy L Rose, Allison M Deal, Sylvain Ladoire, Gilles Créhange, Matthew D Galsky, Jonathan E Rosenberg, Joaquim Bellmunt, Akhila Wimalasingham, Yu-Ning Wong, Lauren C Harshman, Simon Chowdhury, Guenter Niegisch, Michalis Liontos, Evan Y Yu, Sumanta K Pal, Ronald C Chen, Andrew Z Wang, Matthew E Nielsen, Angela B Smith, Matthew I Milowsky
Background: Trimodality bladder preservation therapy (BPT) in muscle invasive bladder cancer (MIBC) includes a maximal transurethral resection followed by concurrent chemoradiotherapy as an alternative to radical cystectomy (RC) in appropriately selected patients, or as a treatment option in non-cystectomy candidates. Several chemotherapy regimens can be used in BPT, but little is known about current practice patterns. Objective: To describe utilization patterns of BPT and associated survival outcomes in MIBC...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035319/the-role-of-transurethral-resection-in%C3%A2-trimodal-therapy-for-muscle-invasive-bladder-cancer
#13
REVIEW
Christopher M Russell, Amir H Lebastchi, Tudor Borza, Daniel E Spratt, Todd M Morgan
While radical cystectomy (RC) with pelvic lymph node dissection (PLND) represents the accepted gold standard for the treatment of muscle-invasive bladder cancer, this treatment approach is associated with significant morbidity. As such, bladder preservation strategies are often utilized in patients who are either deemed medically unfit due to significant comorbidities or whom decline management with RC and PLND secondary to its associated morbidity. In a select group of patients, meeting strict criteria, bladder preservation approaches may be employed with curative intent...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28034491/a-role-of-multimodality-bladder-preserving-therapy-in-patients-with-muscle-invasive-bladder-cancer-plus-hydronephrosis-with-or-without-pelvic-nodal-involvement
#14
Yun Chiang, Jason Chia-Hsien Cheng, Chao-Yuan Huang, Yu-Chieh Tsai, Chia-Chi Lin, Chih-Hung Hsu, Ann-Lii Cheng, Yeong-Shiau Pu
BACKGROUND/PURPOSE: To retrospectively evaluate the failure patterns of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer. METHODS: Patients with muscle-invasive bladder cancer underwent maximal transurethral resection of bladder tumor and induction chemotherapy, followed by concurrent chemoradiotherapy (CCRT). Radiotherapy was given with 45 Gy to the pelvis, 50.4 Gy to the bladder, and 64.8 Gy to the tumor bed. Three protocols of trimodality treatment were used: Protocol A, three cycles of cisplatin and fluorouracil (CF), followed by CCRT with 6 weekly cisplatin; Protocol B, three cycles of weekly paclitaxel plus CF, followed by CCRT with 6 weekly paclitaxel and cisplatin; Protocol C, three cycles of gemcitabine and cisplatin, followed by CCRT with 6 weekly cisplatin...
December 26, 2016: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/28024950/detection-and-clinical-significance-of-circulating-tumor-cells-in-patients-undergoing-radical-cystectomy-for-urothelial-bladder-cancer
#15
Vincenzo Pagliarulo, Patrizia Ancona, Tommasangelo Petitti, Annamaria Salerno, Rossana Spadavecchia, Savino Di Stasi, Luigi Cormio, Buscarini Maurizio, Giuseppe Carrieri, Pasquale Ditonno
INTRODUCTION: Estimation of prognosis is patients undergoing radical cystectomy is often unreliable, as occult disease remains undetected by conventional diagnostic tools. The purpose of this study was to evaluate the feasibility and the clinical significance of a polymerase chain reaction assay to detect cytokeratin 7 (CK7) mRNA expression in peripheral blood cells of patients undergoing radical cystectomy for clinically nonmetastatic bladder cancer. PATIENTS AND METHODS: From 2005 to 2009, 59 patients undergoing radical cystectomy and pelvic lymph node dissection were prospectively investigated...
December 1, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27999236/cd8-t-lymphocyte-subsets-in-bladder-tumor-draining-lymph-nodes
#16
Zahra Faghih, Saeideh Sadat Shobeiri, Ali Ariafar, Mohsen Sarkarian, Shahryar Zeighami, Nazanin Nazari, Saeed Abbasi-Sarvak, Nasrollah Erfani
BACKGROUND: Cytotoxic CD8+ T cells, as essential parts of the adaptive immune system, play pivotal roles in anti-tumor immune responses. It is well documented that cytokine expression profiles and activation status of these cells during anti-tumor immune responses affect the outcome of host-tumor interaction. OBJECTIVE: To investigate the percentages of CD8+ lymphocytes and their subsets in tumor draining lymph nodes of patients with bladder cancer. METHODS: Forty-five patients with bladder cancer, candidate for radical cystectomy, were recruited...
December 2016: Iranian Journal of Immunology: IJI
https://www.readbyqxmd.com/read/27993579/does-the-gross-prosector-impact-pt3-subclassification-or-lymph-node-counts-in-bladder-cancer
#17
Eric M Tretter, Joshua J Ebel, Kamal S Pohar, Debra L Zynger
Gross prosector analysis of perivesicular adipose tumor invasion is the sole differentiator between pT3 substages, and gross evaluation is critical to lymph node identification. Gross prosector impact on pT3 subclassification and lymph node counts in cystectomy specimens resected for bladder cancer has not been previously analyzed. Both pT3 subclassification and total number of lymph nodes removed at radical cystectomy for bladder cancer are considered important components of the pathology report; however, both have controversial prognostic significance...
December 16, 2016: Human Pathology
https://www.readbyqxmd.com/read/27992871/erbb2-expression-as-potential-risk-stratification-for-early-cystectomy-in-patients-with-pt1-bladder-cancer-and-concomitant-carcinoma-in-situ
#18
Johannes Breyer, Wolfgang Otto, Ralph M Wirtz, Bernd Wullich, Bastian Keck, Philipp Erben, Maximilian C Kriegmair, Robert Stoehr, Markus Eckstein, Mark Laible, Kornelia Schlombs, Sebastian Eidt, Stefan Denzinger, Maximilian Burger, Arndt Hartmann
: Background/Aims/Objectives: It is difficult to identify patients with a non-muscle-invasive bladder cancer (NMIBC) at stage pT1 with concomitant carcinoma in situ (Cis) who will benefit from an early cystectomy. METHODS: We retrospectively analyzed clinical data and formalin-fixed paraffin-embedded tissues of patients with NMIBC. Messenger ribonucleic acid (mRNA) expression of progesterone receptor (PGR), estrogen receptor (ESR1), ERBB2, and marker of proliferation Ki-67 (MKI67) was measured by single-step reverse transcription quantitative real-time polymerase chain reaction using RNA-specific TaqMan assays...
December 17, 2016: Urologia Internationalis
https://www.readbyqxmd.com/read/27991416/small-cell-carcinoma-of-the-bladder-20-year-single-institution-retrospective-review
#19
Kyungsuk Jung, Pooja Ghatalia, Samuel Litwin, Eric M Horwitz, Robert G Uzzo, Richard E Greenberg, Rosalia Viterbo, Daniel M Geynisman, Alexander Kutikov, Elizabeth R Plimack, Marc C Smaldone, Yu-Ning Wong, Marijo Bilusic
INTRODUCTION: Small-cell carcinoma of the bladder is a poorly differentiated neoplasm with aggressive behavior. We analyzed clinical outcomes of patients who were treated at our institution to identify an optimal treatment strategy. MATERIALS AND METHODS: Retrospective chart analysis was performed for patients who were treated for small-cell carcinoma of the bladder at Fox Chase Cancer Center between 1995 and 2015. Survival was compared between different treatment periods (before January 2010 vs...
September 30, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27987527/development-validation-and-clinical-application-of-pelvic-lymphadenectomy-assessment-and-completion-evaluation-intraoperative-assessment-of-lymph-node-dissection-after-robot-assisted-radical-cystectomy-for-bladder-cancer
#20
Ahmed A Hussein, Nobuyuki Hinata, Shiva Dibaj, Paul R May, Justen D Kozlowski, Hassan Abol-Enein, Ronney Abaza, Daniel Eun, Mohamed S Khan, James L Mohler, Piyush Agarwal, Kamal Pohar, Richard Sarle, Ronald Boris, Sridhar S Mane, Alan Hutson, Khurshid A Guru
OBJECTIVES: To develop a scoring tool, Pelvic Lymphadenectomy Appropriateness and Completion Evaluation (PLACE), to assess the intraoperative completeness and appropriateness of pelvic lymph node dissection (PLND) following robot-assisted radical cystectomy (RARC). PATIENTS, SUBJECTS AND METHODS: A panel of 11 open and robotic surgeons developed the content and structure of PLACE. The PLND template was divided into three zones. In all, 21 de-identified videos of bilateral robot-assisted PLNDs were assessed by the 11 experts using PLACE to determine inter-rater reliability...
December 17, 2016: BJU International
keyword
keyword
83069
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"